Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

S&P 500, Alphabet Inc Class A, Pfizer Inc, Healthcare Realty Trust Incorporated. Read 's Market Analysis on Investing.com UK.

Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include younger adults, and announced a collaboration with Flagship Pioneering for ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention ...

Organizations that develop sophisticated approaches to IP risk management can protect their exit potential and create ...

Pfizer's latest plot twist includes an expanded European nod for its RSV vaccine, ABRYSVO, and a new autoimmune collab with ...

(Reuters) - Pfizer (NYSE:PFE) has invested $25 million to buy a minority stake in Caribou Biosciences, making it the latest... ByReuters • Jul 06, 2023 Caribou Bioscience Climbs 67% Following ...

We recently published a list of 11 Best Performing NASDAQ Stocks So Far in 2025. In this article, we are going to take a look at where Valneva (NASDAQ:VALN) stands against other best performing NASDAQ ...

A reported 3500 US Food & Drug Administration staff are headed for the guillotine, as part of Trump's broader purge of the health bureaucracy.

For more than three decades, the pharmaceutical sector has been protected from tariffs by a World Trade Organization ...